- Home
- MARA vs CRSP Comparison
MARA vs CRSP Comparison
Compare MARA & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MARA
- CRSP
- Stock Information
- Founded
- MARA 2010
- CRSP 2013
- Country
- MARA United States
- CRSP Switzerland
- Employees
- MARA N/A
- CRSP N/A
- Industry
- MARA EDP Services
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MARA Technology
- CRSP Health Care
- Exchange
- MARA Nasdaq
- CRSP Nasdaq
- Market Cap
- MARA 3.7B
- CRSP 3.4B
- IPO Year
- MARA N/A
- CRSP 2016
- Fundamental
- Price
- MARA $12.66
- CRSP $37.77
- Analyst Decision
- MARA Buy
- CRSP Buy
- Analyst Count
- MARA 12
- CRSP 19
- Target Price
- MARA $22.80
- CRSP $74.35
- AVG Volume (30 Days)
- MARA 35.9M
- CRSP 2.4M
- Earning Date
- MARA 05-08-2025
- CRSP 05-07-2025
- Dividend Yield
- MARA N/A
- CRSP N/A
- EPS Growth
- MARA 62.77
- CRSP N/A
- EPS
- MARA 1.72
- CRSP N/A
- Revenue
- MARA $656,378,000.00
- CRSP $37,314,000.00
- Revenue This Year
- MARA $50.98
- CRSP $51.35
- Revenue Next Year
- MARA $18.26
- CRSP $282.16
- P/E Ratio
- MARA $7.35
- CRSP N/A
- Revenue Growth
- MARA 69.38
- CRSP N/A
- 52 Week Low
- MARA $9.81
- CRSP $30.04
- 52 Week High
- MARA $30.28
- CRSP $67.88
- Technical
- Relative Strength Index (RSI)
- MARA 49.46
- CRSP 49.46
- Support Level
- MARA $9.81
- CRSP $36.74
- Resistance Level
- MARA $13.45
- CRSP $40.13
- Average True Range (ATR)
- MARA 1.16
- CRSP 2.67
- MACD
- MARA 0.21
- CRSP 0.72
- Stochastic Oscillator
- MARA 78.30
- CRSP 76.62
About MARA Marathon Digital Holdings Inc.
MARA Holdings Inc leverages digital asset compute to support the energy transformation. It secures the blockchain ledger and supports the energy transformation by converting clean, stranded, or underutilized energy into economic value.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.